Dr. Stephanie Lunn reports

AURORA AND COPEIA LAUNCH ENGLISH VERSION OF PHYSICIAN EXPERIENCE PLATFORM (PEP), EXPANDING ACCESS TO PEER-REVIEWED MEDICAL CANNABIS CASE STUDIES

Aurora Cannabis Inc. has launched the English-language version of the Physician Experience Platform (PEP), in collaboration with German health care technology leader, Copeia. Developed as a peer-to-peer educational resource for physicians, PEP provides real-world case studies from doctors using medical cannabis as part of patient care.

"The development of the English PEP marks a major milestone for international physician education in medical cannabis, and Aurora is proud to be at the forefront of this work," says Dr. Stephanie Lunn, director of medical and patient affairs at Aurora Cannabis. "By opening access to a broader audience of health care professionals, we're setting a new standard in peer-led clinical knowledge sharing that we believe will have direct impact on the prescribing of medical cannabis."

The English PEP follows the successful rollout of the German version in early 2024. With more than 130 anonymized case studies available, the platform will give health care professionals worldwide access to clinical insights into cannabis-based therapies. Each case includes detailed information such as patient history, treated symptoms, therapeutic outcomes, dosage and product data, and documentation of other therapies before and during the cannabis-based medicine treatment. Health care providers can also search for local product recommendations based on those used in similar case studies.

"Physicians have long faced challenges prescribing medical cannabis -- even when it may be the best option for a patient -- due to its limited integration into established health care education and processes. Uncertainty and skepticism remain, underscoring the need for real-world data to enable personalized care and informed prescribing," says Garvin Hirt, chief executive officer of Copeia. "Copeia's patient case registry delivers firsthand experiences from German physicians to a global audience. PEP lets clinicians search and compare case reports using our comprehensive database that makes physicians' experiences visible and actionable."

The expanded PEP will initially be available to physicians in Canada, United Kingdom, Poland, Malta, the Czech Republic, Australia and New Zealand.

The PEP platform is gated by DocCheck login access, ensuring that only verified health care professionals can view the content. While the English-language platform will initially be read only, Aurora and Copeia are expected to roll out a future version that would allow physicians worldwide to upload and share case studies, creating a truly international medical cannabis study database and deepening cross-border clinical collaboration.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

We seek Safe Harbor.